The Bruton’s Tyrosine Kinase Inhibitor Remibrutinib Exhibits No Impact on Serum Immunoglobulin Levels: Insights from Chronic Spontaneous Urticaria (P10-6.018)

Robert Bermel; Warner Carr; Tanuja Chitnis; Thomas Dörner; Koremasa Hayama; Michihiro Hide; Marcus Maurer; Xavier Montalbán; Gordon Sussman; Heinz Wiendl; Swapnil Dahale; Virginia DeLasHeras; Sibylle Haemmerle; Bernd C. Kieseier; K. Lheritier; Artem Zharkov; Roman Willi; Ana M. Giménez‐Arnau

doi:10.1212/wnl.0000000000206293

Abstract

To assess serum immunoglobulin (Ig) levels over time in a Phase 2b core (NCT03926611) and extension (NCT04109313) study of remibrutinib in patients with chronic spontaneous urticaria (CSU), receiving various doses including 100mg b.i.d., the dosing regimen being evaluated in the Phase 3 REMODEL trials (NCT05147220, NCT05156281) in relapsing multiple sclerosis (MS).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Bermel et al. (2024) studied this question.

synapsesocial.com/papers/68e6fdb8b6db6435876783a7 https://doi.org/10.1212/wnl.0000000000206293

View Full Paper

Ask AI

Bookmark

Share

The Bruton’s Tyrosine Kinase Inhibitor Remibrutinib Exhibits No Impact on Serum Immunoglobulin Levels: Insights from Chronic Spontaneous Urticaria (P10-6.018)

Abstract

Discussion

Cite This Study

The Bruton’s Tyrosine Kinase Inhibitor Remibrutinib Exhibits No Impact on Serum Immunoglobulin Levels: Insights from Chronic Spontaneous Urticaria (P10-6.018)

Abstract

Discussion

Cite This Study

Keep reading

Keep reading